Efektivitas dan keamanan terapi dengan rejimen yang mengandung linezolid dalam pengobatan multidrug-resistant tuberculosis (MDR-TB): Kajian Sistematik

Objective: To systematically evaluate the existing evidence regarding the efficacy and safety of therapy with regimens containing linezolid in the treatment of Multidrug‐ resistant tuberculosis (MDR-TB). Data source: The search strategy was undertaken using PubMed, Cochrane, and ScienceDirect databases. Review method: Searching the literature without changing the type of research or year of publication in which articles published until March 14, 2021, are involved in this literature review. The search strategy undertaken using PubMed, Cochrane, and ScienceDirect with the keywords "linezolid", "treatment", "tuberculosis" and "multidrugresistant" which were combined with the use of a Boolean operator "AND". Results: A total of seven studies were included in the final study. Linezolid had efficacy in MDR-TB patients with a much higher level of treatment support in the linezolid therapy group than in the control group (not using linezolid). However, the side effects that occurred were categorized as hematologic, gastrointestinal, neurological, and dermatological which generally occurred after 278 days of use. Severe diarrhea and nausea shortly after starting treatment were felt in 12.5% of patients. The main side effects controlled with linezolid (anemia, thrombocytopenia, and/or polyneuropathy), which generally required discontinuation were reported in 1 study and required discontinuation in 27 (77%) cases. The most important side effect is peripheral neuropathy, necessary to monitor the report by the 5 articles included in the final study. Conclusion: Available evidence has shown linezolid therapy to be effective against MDR-TB treatment. Monitored for the incidence of major adverse neurotoxicity (peripheral or optic neuropathy). To follow side effects and improve clinical outcomes, a combined high dose (1200 mg daily) for the intensive phase followed by a lower dose (300-600 mg daily) for the continuous phase is recommended along with an effective patient to increase the current dose and monitoring.